Allena Pharmaceuticals Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$146M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Allena Pharmaceuticals's estimated annual revenue is currently $6M per year.(i)
  • Allena Pharmaceuticals received $53.0M in venture funding in December 2015.
  • Allena Pharmaceuticals's estimated revenue per employee is $90,224
  • Allena Pharmaceuticals's total funding is $146M.
  • Allena Pharmaceuticals's current valuation is $37.1M. (January 2022}

Employee Data

  • Allena Pharmaceuticals has 67 Employees.(i)
  • Allena Pharmaceuticals grew their employee count by 10% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. Allena's proprietary technological approach enables the design, formulation and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. This approach utilizes the GI tract to degrade metabolites, such as oxalate and urate, reducing plasma and urine levels, and in turn, reducing their disease burden on the kidney over time.

keywords:Biotechnology,Cleantech,Healthcare,Mobile,Pharmaceuticals,Wind Power

$146M

Total Funding

67

Number of Employees

$6M

Revenue (est)

10%

Employee Growth %

$37.1M

Valuation

N/A

Accelerator

Allena Pharmaceuticals News

2014-12-04 - Allena Pharmaceuticals Completes $25m Series B Financing

Allena Pharmaceuticals, Inc., a Newton, Mass.-based specialty biopharmaceutical company, completed a $25m Series B financing. The round was led by HBM Partners, with participation from existing investors Frazier Healthcare, Third Rock Ventures, Bessemer Venture Partners and new investor Pharmst ...

2015-12-09 - Allena Pharmaceuticals Completes $53M Series C Financing

Allena Pharmaceuticals, Inc., a Newton, MA-based biopharmaceutical company focused on developing and commercializing innovative non-systemic oral protein therapeutics to treat metabolic and orphan diseases, completed a $53m Series C financing. The round was led by Partner Fund Management with p ...

2021-03-09 - ALLENA PHARMACEUTICALS, INC. Allena Pharmaceuticals : Corporate Presentation March 2021

Company Presentation March 2021 Allena Pharmaceuticals, Inc. These slides, and the accompanying presentation, contain forward-looking statements and information. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "inten ...

09/03/2019 - Allena Pharmaceuticals: Unique Treatment For Enteric Hyperoxaluria Not Reflected In Valuation

Allena Pharmaceuticals drug, Reloxaliase, is in Phase 3 clinical trials for enteric hyperoxaluria (EH), a leading cause of the most common type ...

09/08/2019 - -$0.48 EPS Expected for Allena Pharmaceuticals Inc (NASDAQ:ALNA) This Quarter

Brokerages expect Allena Pharmaceuticals Inc (NASDAQ:ALNA) to report ($0.48) earnings per share (EPS) for the current quarter, according to ...

09/03/2019 - Allena Pharmaceuticals to Participate in Upcoming Investor Conferences in September

NEWTON, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.2M6749%N/A
#2
$8.4M6726%N/A
#3
$8.9M6811%N/A
#4
$13.7M69N/AN/A
#5
N/A690%N/A

Allena Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2011-11-17$15.0MABessemer Venture Partners, Frazier HealthcareArticle
2014-12-05$25.0MBHBM PartnersArticle
2015-12-10$53.0MCMultipleArticle